‘Frustrated’ JPMorgan remains buyer of Insulet after Q2 beat

JPMorgan analyst Robbie Marcus is “frustrated” to see shares of Insulet down following last week’s Q2 sales beat. The firm says 2024 earnings consensus estimates are now 26% higher than six months ago and 41% higher than a year ago, while 2025 earnings estimates are up 14% and 24%, respectively, over the same time frame. The business is “very healthy, forecasts keep moving higher, margins are surprising to the upside, and with now material FCF generation above earnings growth, this is a thriving business,” the analyst tells investors in a research note. With the stock down year-to-date JPMorgan remains a buyer with n Overweight rating and $250 price target.